Weight-loss drug developer Metsera reveals wider loss in US IPO filing
(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday. The terms of the IPO were not disclosed in the filing. Strong equity markets, falling interest rates and hopes of a friendlier regulatory environment under the incoming Trump administration have…